Latest Insider Transactions at Generation Bio Co. (GBIO)
This section provides a real-time view of insider transactions for Generation Bio Co. (GBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Generation Bio Co. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Generation Bio Co.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$37,500
$25.04 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.25%
|
$34,500
$23.24 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-0.75%
|
$72,000
$24.96 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,518
-0.53%
|
$87,950
$25.19 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+1.05%
|
$17,590
$5.16 P/Share
|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
58
-4.4%
|
$1,508
$26.08 P/Share
|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,950
-93.39%
|
$804,700
$26.08 P/Share
|
|
Jun 24
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
31,008
-48.9%
|
$806,208
$26.08 P/Share
|
|
Jun 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
116
-7.71%
|
$2,900
$25.39 P/Share
|
|
Jun 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
62,493
-42.18%
|
$1,562,325
$25.39 P/Share
|
|
Jun 23
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
62,609
-24.94%
|
$1,565,225
$25.39 P/Share
|
|
Jun 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
108
-6.26%
|
$2,592
$24.98 P/Share
|
|
Jun 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
58,469
-21.57%
|
$1,403,256
$24.98 P/Share
|
|
Jun 22
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
58,577
-13.92%
|
$1,405,848
$24.98 P/Share
|
|
Jun 21
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
118
-5.9%
|
$2,832
$24.97 P/Share
|
|
Jun 21
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
63,774
-15.12%
|
$1,530,576
$24.97 P/Share
|
|
Jun 21
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
63,892
-10.51%
|
$1,533,408
$24.97 P/Share
|
|
Jun 16
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
100,000
-7.32%
|
-
|
|
Jun 16
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-10.97%
|
-
|
|
Jun 15
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$42,000
$28.08 P/Share
|
|
Jun 15
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Jun 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-2.94%
|
$162,000
$27.23 P/Share
|
|
Jun 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+2.86%
|
$24,000
$4.59 P/Share
|
|
May 27
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$51,000
$34.05 P/Share
|
|
May 27
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
May 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
400
-0.2%
|
$12,400
$31.05 P/Share
|
|
May 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.1%
|
$800
$2.6 P/Share
|
|
May 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,600
-1.4%
|
$266,600
$31.2 P/Share
|
|
May 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+3.99%
|
$0
$0.6 P/Share
|
|
May 03
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.42%
|
$350,000
$35.9 P/Share
|
|
May 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-89.8%
|
$87,500
$35.92 P/Share
|
|
May 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Apr 23
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$350,000
$35.1 P/Share
|
|
Apr 22
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$82,500
$33.32 P/Share
|
|
Apr 22
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Apr 22
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$51,000
$34.03 P/Share
|
|
Apr 22
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 21
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$46,500
$31.07 P/Share
|
|
Apr 21
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 16
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$42,000
$28.03 P/Share
|
|
Apr 16
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 14
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
23,413
-72.51%
|
$608,738
$26.59 P/Share
|
|
Apr 14
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
23,413
-72.51%
|
$608,738
$26.59 P/Share
|
|
Apr 13
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,145
-38.84%
|
$1,078,625
$25.31 P/Share
|
|
Apr 13
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
43,145
-38.84%
|
$1,078,625
$25.31 P/Share
|
|
Apr 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-1.48%
|
$156,000
$26.45 P/Share
|